Login to Your Account

Bydureon Falls to Victoza in Head-on Type II Diabetes Match

By Mari Serebrov

Friday, March 4, 2011
In an unrequired, head-to-head trial, Amylin Pharmaceuticals Inc. and Eli Lilly and Co.'s weekly diabetes candidate Bydureon came up short against Novo Nordisk A/S' daily Victoza.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription